These results are consistent with those obtained using the in vitro model used in this study, which indicates that NR1D2 could be used as a target for treating this type of cancer in patients with tumours harbouring a wild type p53, and, therefore, to develop personalised medicine in CRC. Here, TP53 is linked to colorectal carcinoma.